Home / NET

NET

October 13, 2021

Improving target volume delineation for 3D image-based dosimetry in PRRT

Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues is currently the most effective molecular radiotherapy (MRT) treatment for patients who suffer from neuroendocrine tumours (NET) with metastasised disease. In PRRT the treatment is systemic and the most frequent treatment protocol is to administer 7.4GBq of Lu-177 up to four times with a six to […]

Dr Emiliano Spezi, Dr Salvatore Berenato

Cardiff University, Velindre Cancer Centre

Read Article

July 14, 2021

Normal pancreatic appearances of 68Ga-DOTA

Neuroendocrine tumours (NET) arise from the malignant growth of neuroendocrine cells, a system of paracrine cells distributed throughout the body. Most NETs arise from the gastrointestinal tract, most commonly in the small bowel and the lungs. About half of NETs occur in the small bowel and about one quarter in the lungs. Other forms of […]

Dr Guglielmo La Torre, Dr Simon Hughes

University Hospitals Birmingham NHS Foundation Trust

Read Article

October 16, 2019

SPECT/CT in oncology

Radionuclide imaging can demonstrate whole body functional/metabolic information and plays an important role in oncology clinical and research practice. It is integral to many clinical pathways, assisting in diagnosis and staging, pre-operative localisation, monitoring response and detecting recurrence. However, planar scintigraphy and SPECT lack anatomical and structural details resulting in low specificity and sensitivity with […]

Dr Fraser Hendry, Dr Sai Han

Glasgow Royal Infirmary, Gartnavel General Hospital

Read Article

April 13, 2018

Is 68Ga-DOTA-PETCT more accurate than 123I/131I-mIBG imaging in the diagnosis of phaeochromocytoma?

Phaeochromocytoma is a rare neuroendocrine tumour (NET), with an annual incidence of approximately 1/100,000. Arising from the adrenal medulla, phaeochromocytomas constitute approximately 80-85% of all chromaffin cell tumours. Phaeochromocytomas secrete excessive catecholamines, inducing hypertension and tachycardia. Provisional diagnoses are made following clinical examination and biochemical analysis, with anatomical imaging to localise the tumour and functional […]

Hollie Hadwen

University of Suffolk

Read Article

April 14, 2017

Molecular medicine imaging of neuroendocrine tumours

Neuroendocrine tumours (NETs) are a diverse, highly heterogeneous group of neoplasms derived from endocrine cells found in the neural crest. NETs typically display endocrine metabolism and slow growth, while displaying a wide range of presentations and clinical symptoms. Demonstrating typically small lesions, with varying anatomical localisation, diagnosis is typically in the advanced stages of tumour […]

Andrew Farnworth, Dr Emmanouil Panagiotidis

Royal Liverpool University Hospital

Read Article

August 19, 2016

Newer radionuclide therapies

Radionuclide therapy (RNT), also known as molecular radiotherapy (MRT), utilises unsealed ionising radiation to target particular tissues. RNT depends on the properties of the radionuclides and tracer conjugates that selectively binds to cell receptors. The majority of radionuclides used in RNT are beta (β)-particles, although there is an established role and also emerging applications using […]